title: DNA vaccine protection against challenge with simian/human immunodeficiency virus 89.6 in rhesus macaques.
abstract: Twelve Rhesus macaques were immunized by intramuscular injection of naked DNA encoding the SlVmac gag and nef genes, HIV-1 89.6 env and rev genes and the simian interleukin-12 (IL-12) gene. Six of the animals also received two intramuscular injections of gp140 89.6 formulated in QS21. The monkeys were challenged by the intrarectal route, in parallel with six control monkeys, using 750 TCID50 of SHIV-89.6. Virus recovery in PBMC by co-cultivation was as follows: controls: six out of six; DNA only: five out of six; DNA + protein: two out of six. The five animals that remained virus free after this first challenge were challenged a second time, again by the intrarectal route and in parallel with four naive controls, using 600 TCID50 of pathogenic SHIV-89.6P. A rapid CD4 cell count decline was observed in the four control monkeys as well as in the monkey vaccinated with DNA only, but in none of the four animals immunized with DNA + protein. No virus was recovered from PBMC in two of these monkeys, and viral RNA loads in plasma were greatly reduced in three of them as compared with the controls. Absence of virus in PBMC was ascertained by whole blood transfusion to naive recipients. Altogether, this shows that the DNA prime-protein boost vaccine regimen could provide some protection against mucosal SHIV infection in rhesus monkeys, whereas DNA alone was ineffective.
authors.affiliation: Molecular Virology Unit, Institut Pasteur, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Habel
authors.forename: C
authors.initials: C
authors.lastname: Chanel
authors.forename: R
authors.initials: R
authors.lastname: Le Grand
authors.forename: F
authors.initials: F
authors.lastname: Martinon
authors.forename: L
authors.initials: L
authors.lastname: Couillin
authors.forename: C
authors.initials: C
authors.lastname: Moog
authors.forename: R
authors.initials: R
authors.lastname: Doms
authors.forename: M C
authors.initials: MC
authors.lastname: Gauduin
authors.forename: B
authors.initials: B
authors.lastname: Hurtrel
authors.forename: J G
authors.initials: JG
authors.lastname: Guillet
authors.forename: A M
authors.initials: AM
authors.lastname: Aubertin
authors.forename: M
authors.initials: M
authors.lastname: Girard
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000235:genetics; D000285:Administration, Rectal; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D018791:CD4 Lymphocyte Count; D015686:Gene Products, env / Q000008:administration & dosage / Q000276:immunology; D015483:HIV Antibodies / Q000096:biosynthesis; D015497:HIV-1 / Q000235:genetics / Q000276:immunology; D006801:Humans; D018928:Immunity, Mucosal; D007117:Immunization, Secondary; D007273:Injections, Intramuscular; D008253:Macaca mulatta; D018449:SAIDS Vaccines / Q000008:administration & dosage* / Q000235:genetics; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000235:genetics; D054299:env Gene Products, Human Immunodeficiency Virus
chemical_list: D016915:AIDS Vaccines; D000914:Antibodies, Viral; D015686:Gene Products, env; D015483:HIV Antibodies; D018449:SAIDS Vaccines; D019444:Vaccines, DNA; D054299:env Gene Products, Human Immunodeficiency Virus; C097729:gp140 envelope protein, Human immunodeficiency virus 1